Diagnosis of acute myeloid leukemia
according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol.
The prognostic relevance of BAALC and ERG expression levels in cytogenetically normal pediatric acute myeloid leukemia
The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia
Clinical characterization of acute myeloid leukemia
with myelodysplasia- related changes as defined by the 2008 WHO classification system.
Eastern Cooperative Oncology Group Study of the cytochemistry of adult acute myeloid leukemia
by correlation of subtypes with response and survival.
7 It is the most commonly recognized mutated gene in cytogene-tically normal acute myeloid leukemia
Now we know that patients can receive appropriate therapy without increased risk of developing acute myeloid leukemia
and myelodysplastic syndrome in the first three years.
Acute myeloid leukemia
occurs when the precursors of our own blood cells become corrupted by mutations in their DNA.
A distinctive nuclear morphology in acute myeloid leukemia
is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication.
Treatment of acute myeloid leukemia
in elderly patients (traditionally defined as patients 65 years or older) is approached differently primarily due to the presence of multiple co-morbidities.
After investigators controlled for age, race, and grade and stage of prostate cancer, patients who received external beam radiation therapy had nearly a twofold greater risk of developing acute myeloid leukemia
15 years after their diagnosis than did patients who did not receive therapy, Rohit P.
FLT3 is considered to be one of the major causes of acute myeloid leukemia
Myeloid sarcoma (MS) is an extramedullary myeloid tumor (granulocytic sarcoma) that can occur in one of three clinical settings: (1) in patients who have a history of acute myeloid leukemia
(AML), during active disease or a recurrence: (2) in patients with chronic myeloproliferative disorder or myelodysplastic syndromes, who are at increased risk of blast transformation or acute leukemia; or (3) in patients with no history of hematologic disease, although it commonly predates the development of leukemia, often within 1 year.
childhood leukemia cases diagnosed from 1975 to 1995, while acute myeloid leukemia
(AML) accounted for 16%, according to data from the Surveillance, Epidemiology, and End Results registry.
have initiated a clinical trial of MG98, a second-generation antisense inhibitor of DNA methyltransferase, in patients with advanced myelodysplasia (MDS) or relapsed/refractory acute myeloid leukemia